SCHEMBL7961042

SCHEMBL7961042

COC(=O)C(c1ccccc1)n1nc(Cc2cn(C)c3cccc(C)c23)c2ccccc2c1=O

nearest known ligand 0.83

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CMA1 P23946 19/20 0.83
▸ CTSG P08311 1/20 0.42
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851876 0.93 CMA1 (0.83) CMA1CTSG
SCHEMBL7951286 0.91 CMA1 (1.00) CMA1CTSGPOLB
SCHEMBL7966175 0.90 CMA1 (0.81) CMA1POLB
SCHEMBL18900823 0.85 CMA1 (0.79) CMA1CTSGPOLB
SCHEMBL7960485 0.82 CMA1 (0.84) CMA1CTSG
SCHEMBL7951279 0.82 CMA1 (1.00) CMA1CTSG
SCHEMBL7962647 0.81 CMA1 (0.78) CMA1POLB
SCHEMBL7960258 0.80 CMA1 (1.00) CMA1CTSG
SCHEMBL3418056 0.80 CMA1 (1.00) CMA1POLB
SCHEMBL18900837 0.79 CMA1 (0.77) CMA1CTSGPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2323991-B1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2017-05-31 — — EP disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-8969348-B2 Chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-03-03 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
US-20120129863-A1 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-24 — — US disclosed
WO-2010019417-A2 CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129863-A1 CHYMASE INHIBITORS CMA1, CPA3, SERPINB1 CMA1 1/4885CTSG 14/4885POLB 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback